SCHEMBL101334

SCHEMBL101334

COc1cccc(CC#N)c1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.55
IDO1 P14902 2/20 0.55
AGXT P21549 2/20 0.55
CHRM2 P08172 3/20 0.51
CHRM1 P11229 2/20 0.51
CHRM3 P20309 2/20 0.51
CMA1 P23946 1/20 0.50
SIGMAR1 Q99720 2/20 0.49
MAOB P27338 2/20 0.49
AOC3 Q16853 1/20 0.49
ENPP2 Q13822 1/20 0.49
LPO P22079 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8784075 0.93 TAAR1 (0.49) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL28141102 0.89 CMA1 (0.45) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL8992947 0.88 LTA4H (0.49) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL10545623 0.88 SMN1; SMN2 (0.56) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL8992807 0.84 CNR2 (0.46) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL8993396 0.84 CNR2 (0.48) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL27295522 0.82 MAOB (0.47) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL1233549 0.81 MEN1 (0.66) TAAR1IDO1AGXTCHRM2CHRM1
SCHEMBL2294721 0.81 TP53 (0.50) CHRM2CHRM1CHRM3ENPP2
SCHEMBL8596617 0.81 SMN1; SMN2 (0.56) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720073-A1 SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS Kura Oncology, Inc. (US) 2026-04-08 EP claimed
WO-2024245364-A1 SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS KURA ONCOLOGY, INC. (US) 2024-12-05 WO claimed
CN-114248574-A Application of thermo-reversible piezochromic dye in inkless printing technology 天津理工大学 2022-03-29 CN claimed
US-7923110-B2 Metal nanoparticle having a self-assembled monolayer on its surface, and formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2011-04-12 US claimed
US-20080020317-A1 Novel metal nanoparticle and formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-01-24 US claimed
US-20080003363-A1 Novel metal nanoparticle and method for formation of conductive pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-01-03 US claimed
US-5220019-A Process for the preparation of diethyl 2-]2-cyano-5-(dimethylamino)-2-(3-methoxyphenyl)-1,1-dimethylpentyl]propandioate G. D. SEARLE & CO. (US) 1993-06-15 US claimed
EP-0448972-A2 Process for preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines G.D. Searle & Co. (US) 1991-10-02 EP claimed
US-20260125390-A1 SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME KURA ONCOLOGY INC (US) 2026-05-07 US disclosed
EP-4720073-A1 SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS Kura Oncology, Inc. (US) 2026-04-08 EP disclosed
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 US disclosed
US-12466835-B1 Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same KURA ONCOLOGY, INC. (US) 2025-11-11 US disclosed
WO-2025105873-A1 EASILY INSERTABLE AND REMOVABLE MENSTRUAL CUP FOR PREVENTING COLORING 주식회사 올담 2025-05-22 WO disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 EP disclosed
US-4178460-A INTERMEDIATES FOR INSECTICIDES AMERICAN CYANAMID CO. (US) 1979-12-11 US disclosed
US-4072716-A Bicycloalkane derivatives SCHERING AKTIENGESELLSCHAFT (DT) 1978-02-07 US disclosed
US-4051188-A NOVEL BICYCLOALKANE DERIVATIVES AND THE PRODUCTION THEREOF SCHERING AKTIENGESELLSCHAFT (DT) 1977-09-27 US disclosed
US-4008253-A Bicycloalkanes SCHERING AKTIENGESELLSCHAFT (DT) 1977-02-15 US disclosed
US-3944571-A ANTIARTHRITIC SMITHKLINE CORPORATION (US) 1976-03-16 US disclosed
US-3817985-A NEW N-CYCLOPROPYLMETHYL AZETIDINE COMPOUNDS AND PROCESS FOR THEIR PRODUCTION PARKE DAVIS & CO 1974-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125390-A1 SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME FDPS, PCTP, MTTP TAAR1 4095/4885IDO1 4800/4885AGXT 1376/4885
US-12466835-B1 Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same FNTA, SF3B1, SF3A1 TAAR1 4883/4885IDO1 4824/4885AGXT 2459/4885
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA TAAR1 4477/4885IDO1 2546/4885AGXT 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.